INTERVENTION 1:	Intervention	0
Arm I (ACT)	Intervention	1
Patients receive 41.25 mg/m2 of doxorubicin IV over 24 hours on days -9 to -6, 100 mg/kg of cyclophosphamide IV over 2 hours on day -5, and 725 mg/m2 of paclitaxel IV over 24 hours on day -4. PBSC are reinfused on days -2 and 0. G-CSF at 5 ug/kg IV is administered beginning on day 0 and continuing until blood counts recover.	Intervention	2
doxorubicin	CHEBI:28748,BAO:0000639	32-43
cyclophosphamide	CHEBI:4026	92-108
day	UO:0000033	64-67
day	UO:0000033	128-131
day	UO:0000033	184-187
day	UO:0000033	214-217
day	UO:0000033	278-281
paclitaxel	CHEBI:45863	153-163
blood	UBERON:0000178	305-310
filgrastim: Given IV or subcutaneously	Intervention	3
cyclophosphamide: Given IV	Intervention	4
cyclophosphamide	CHEBI:4026	0-16
doxorubicin hydrochloride: Given IV	Intervention	5
doxorubicin hydrochloride	CHEBI:31522	0-25
paclitaxel: Given IV	Intervention	6
paclitaxel	CHEBI:45863	0-10
peripheral blood stem cell transplantation: Patients receive autologous peripheral blood stem cells	Intervention	7
peripheral	HP:0030646	0-10
peripheral	HP:0030646	72-82
blood	UBERON:0000178	11-16
blood	UBERON:0000178	83-88
INTERVENTION 2:	Intervention	8
Arm II (STAMP V)	Intervention	9
Patients receive cyclophosphamide 1.5 g/m2/day IV, carboplatin 200 mg/m2/day IV, and thiotepa 125 mg/m2/day IV over 24 hours on days -7 to -4. PBSC are reinfused on day -2 and 0 and G-CSF at 5ug/kg IV is administered as in arm I.	Intervention	10
cyclophosphamide	CHEBI:4026	17-33
carboplatin	CHEBI:31355	51-62
thiotepa	CHEBI:9570	85-93
day	UO:0000033	43-46
day	UO:0000033	73-76
day	UO:0000033	104-107
day	UO:0000033	128-131
day	UO:0000033	165-168
filgrastim: Given IV or subcutaneously	Intervention	11
carboplatin: Given IV	Intervention	12
carboplatin	CHEBI:31355	0-11
cyclophosphamide: Given IV	Intervention	13
cyclophosphamide	CHEBI:4026	0-16
thiotepa: Given IV	Intervention	14
thiotepa	CHEBI:9570	0-8
peripheral blood stem cell transplantation: Patients receive autologous peripheral blood stem cells	Intervention	15
peripheral	HP:0030646	0-10
peripheral	HP:0030646	72-82
blood	UBERON:0000178	11-16
blood	UBERON:0000178	83-88
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically proven high-risk primary breast cancer with less than 60% chance of progression-free survival of 3 years from diagnosis	Eligibility	1
breast cancer	DOID:1612	40-53
Stage II with at least 10 positive axillary nodes OR	Eligibility	2
Stage IIIA or IIIB	Eligibility	3
No histologically proven bone marrow metastasis	Eligibility	4
bone marrow	UBERON:0002371	25-36
No CNS metastasis	Eligibility	5
Hormone receptor status:	Eligibility	6
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Hormone receptor status known	Eligibility	7
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
PATIENT CHARACTERISTICS:	Eligibility	8
patient	HADO:0000008,OAE:0001817	0-7
Age:	Eligibility	9
age	PATO:0000011	0-3
Physiological age 60 or under	Eligibility	10
age	PATO:0000011	14-17
Menopausal status:	Eligibility	11
Not specified	Eligibility	12
Performance status:	Eligibility	13
Karnofsky 80-100%	Eligibility	14
Life expectancy:	Eligibility	15
See Disease Characteristics	Eligibility	16
disease	DOID:4,OGMS:0000031	4-11
Hematopoietic:	Eligibility	17
Neutrophil count at least 1,500/mm^3	Eligibility	18
Platelet count at least 100,000/mm^3	Eligibility	19
platelet count	CMO:0000029	0-14
Hepatic:	Eligibility	20
Bilirubin no greater than 1.5 mg/dL	Eligibility	21
SGOT or SGPT no greater than 2 times upper limit of normal	Eligibility	22
Hepatitis B antigen negative	Eligibility	23
hepatitis b	DOID:2043	0-11
antigen	CHEBI:59132	12-19
Renal:	Eligibility	24
Creatinine no greater than 1.2 mg/dL	Eligibility	25
creatinine	CHEBI:16737	0-10
Creatinine clearance at least 70 mL/min	Eligibility	26
creatinine clearance	CMO:0000765	0-20
No prior hemorrhagic cystitis	Eligibility	27
hemorrhagic cystitis	DOID:0050859	9-29
Cardiovascular:	Eligibility	28
Ejection fraction at least 55% by MUGA	Eligibility	29
ejection fraction	CMO:0000180	0-17
No prior significant valvular heart disease or arrhythmia	Eligibility	30
heart disease	DOID:114	30-43
arrhythmia	HP:0011675	47-57
Pulmonary:	Eligibility	31
FEV_1 at least 60% of predicted	Eligibility	32
pO_2 at least 85 mm Hg on room air	Eligibility	33
pCO_2 at least 43 mm Hg on room air	Eligibility	34
DLCO at least 60% lower limit of predicted	Eligibility	35
Other:	Eligibility	36
No other prior malignancy except squamous cell or basal cell skin cancer or stage I or carcinoma in situ of the cervix	Eligibility	37
skin cancer	DOID:4159	61-72
carcinoma	HP:0030731,DOID:305	87-96
No CNS dysfunction that would preclude compliance	Eligibility	38
HIV negative	Eligibility	39
No sensitivity to E. coli-derived products	Eligibility	40
Not pregnant	Eligibility	41
Fertile patients must use effective contraception	Eligibility	42
PRIOR CONCURRENT THERAPY:	Eligibility	43
Biologic therapy:	Eligibility	44
Not specified	Eligibility	45
Chemotherapy:	Eligibility	46
At least 4 weeks since prior chemotherapy	Eligibility	47
No prior doxorubicin of total dose exceeding 240 mg/m^2	Eligibility	48
doxorubicin	CHEBI:28748,BAO:0000639	9-20
No prior paclitaxel of total dose of at least 750 mg/m^2	Eligibility	49
paclitaxel	CHEBI:45863	9-19
No more than 12 months since prior conventional-dose adjuvant chemotherapy	Eligibility	50
adjuvant	CHEBI:60809	53-61
Endocrine therapy:	Eligibility	51
At least 4 weeks since prior hormonal therapy	Eligibility	52
Radiotherapy:	Eligibility	53
radiotherapy	OAE:0000235	0-12
At least 4 weeks since prior radiotherapy	Eligibility	54
radiotherapy	OAE:0000235	29-41
No prior radiation to the left chest wall	Eligibility	55
left	HP:0012835	26-30
chest	UBERON:0001443	31-36
Surgery:	Eligibility	56
surgery	OAE:0000067	0-7
Not specified	Eligibility	57
Outcome Measurement:	Results	0
Five-Year Relapse-free Survival	Results	1
RFS events included death or disease recurrence. Patients who did not experience disease recurrence or death were censored at the date of last follow-up. Survival rates were estimates using the Kaplan-Meier method.	Results	2
death	OAE:0000632	20-25
death	OAE:0000632	103-108
disease	DOID:4,OGMS:0000031	29-36
disease	DOID:4,OGMS:0000031	81-88
Time frame: Five years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Arm I (ACT)	Results	5
Arm/Group Description: Patients receive 41.25 mg/m2 of doxorubicin IV over 24 hours on days -9 to -6, 100 mg/kg of cyclophosphamide IV over 2 hours on day -5, and 725 mg/m2 of paclitaxel IV over 24 hours on day -4. PBSC are reinfused on days -2 and 0. G-CSF at 5 ug/kg IV is administered beginning on day 0 and continuing until blood counts recover.	Results	6
doxorubicin	CHEBI:28748,BAO:0000639	55-66
cyclophosphamide	CHEBI:4026	115-131
day	UO:0000033	87-90
day	UO:0000033	151-154
day	UO:0000033	207-210
day	UO:0000033	237-240
day	UO:0000033	301-304
paclitaxel	CHEBI:45863	176-186
blood	UBERON:0000178	328-333
filgrastim: Given IV or subcutaneously	Results	7
cyclophosphamide: Given IV	Results	8
cyclophosphamide	CHEBI:4026	0-16
doxorubicin hydrochloride: Given IV	Results	9
doxorubicin hydrochloride	CHEBI:31522	0-25
paclitaxel: Given IV	Results	10
paclitaxel	CHEBI:45863	0-10
peripheral blood stem cell transplantation: Patients receive autologous peripheral blood stem cells	Results	11
peripheral	HP:0030646	0-10
peripheral	HP:0030646	72-82
blood	UBERON:0000178	11-16
blood	UBERON:0000178	83-88
Overall Number of Participants Analyzed: 21	Results	12
Measure Type: Number	Results	13
Unit of Measure: percentage of participants  47        (24 to 67)	Results	14
Results 2:	Results	15
Arm/Group Title: Arm II (STAMP V)	Results	16
Arm/Group Description: Patients receive cyclophosphamide 1.5 g/m2/day IV, carboplatin 200 mg/m2/day IV, and thiotepa 125 mg/m2/day IV over 24 hours on days -7 to -4. PBSC are reinfused on day -2 and 0 and G-CSF at 5ug/kg IV is administered as in arm I.	Results	17
cyclophosphamide	CHEBI:4026	40-56
carboplatin	CHEBI:31355	74-85
thiotepa	CHEBI:9570	108-116
day	UO:0000033	66-69
day	UO:0000033	96-99
day	UO:0000033	127-130
day	UO:0000033	151-154
day	UO:0000033	188-191
filgrastim: Given IV or subcutaneously	Results	18
carboplatin: Given IV	Results	19
carboplatin	CHEBI:31355	0-11
cyclophosphamide: Given IV	Results	20
cyclophosphamide	CHEBI:4026	0-16
thiotepa: Given IV	Results	21
thiotepa	CHEBI:9570	0-8
peripheral blood stem cell transplantation: Patients receive autologous peripheral blood stem cells	Results	22
peripheral	HP:0030646	0-10
peripheral	HP:0030646	72-82
blood	UBERON:0000178	11-16
blood	UBERON:0000178	83-88
Overall Number of Participants Analyzed: 51	Results	23
Measure Type: Number	Results	24
Unit of Measure: percentage of participants  55        (41 to 68)	Results	25
Adverse Events 1:	Adverse Events	0
Total: 0/21 (0.00%)	Adverse Events	1
Adverse Events 2:	Adverse Events	2
Total:	Adverse Events	3
